Publication | Open Access

Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial

ThrombosisPulmonary EmbolismHypertensionSubcutaneous TreprostinilPhase 3Cardiovascular DiseasePulmonary Arterial HypertensionPulmonary MedicinePublic HealthMedicinePulmonary Vascular DiseaseAnesthesiology